A disintegrin and metalloproteinase 33 (ADAM33) has been identified as an asthma susceptibility gene; however, the role of ADAM33 in the pathogenesis and progression of asthma remains to be elucidated. As ADAM33 is predominantly expressed in airway smooth muscle cells (ASMCs), it is feasible to investigate whether ADAM33 protein expression is correlated with ASMC mechanics that are ultimately responsible for airway hyperresponsiveness in asthma. To determine this, Sprague Dawley rats were sensitized with ovalbumin (OVA) for up to 12 weeks to simulate asthma symptoms. Subsequently, ASMCs were isolated from the rats and cultured in vitro. The protein expression of ADAM33 and cytoskeletal proteins (including F-actin and vinculin), cell stiffness and contractility, as well as traction force were measured. The results demonstrated that compared with the non-sensitized rats, the protein expression of ADAM33 in ASMCs from the OVA-sensitized rats increased in a time-dependent manner, reaching a maximum level at 4 weeks of sensitization and gradually subsiding as OVA sensitization continued (P<0.001). The cell stiffness, traction force and expression of vinculin and F-actin changed similarly, resulting in a positive correlation with ADAM33 protein expression (Pearson's correlation coefficient, 0.864, 0.716, 0.774 and 0.662, respectively;. The in vivo results of OVA-induced ADAM33 protein expression and its association with the mechanics of ASMCs suggested that ADAM33 is a mediator of ASMC dysfunction in asthma, and may provide a rationale for the therapeutic targeting of ADAM33 in the treatment of asthma.
Introduction
Asthma is a common chronic airway disease that is characterized by airway inflammation, airway tissue remodeling and airway hyperresponsiveness (AHR) (1, 2) . Although the symptoms of asthma are largely controllable, the disease is often not completely curable at present. This is generally attributed to the absence of a complete understanding of the mechanism(s) of asthma pathogenesis. Previously, complex interactions between multiple genetic and environmental factors contributing to the pathogenesis of asthma have been demonstrated (3) . Thus, a full investigation of the genes associated with asthma is required to ascertain their roles in mediating airway pathologies.
In the present study, one particular gene of interest, a disintegrin and metalloproteinase 33 (ADAM33), was observed for its correlation with the mechanics of airway smooth muscle cells (ASMCs) in ovalbumin (OVA)-sensitized rat models of asthma. In human studies, ADAM33 has been identified as an asthma susceptibility gene (1, (4) (5) (6) (7) (8) . Subsequently, the correlations between the ADAM33 gene and airway inflammation and airway tissue remodeling have been demonstrated (9, 10) . However, the correlation between the ADAM33 protein and AHR that is equally, if not more important than airway inflammation and tissue remodeling in asthma, remains to be studied. AHR is determined by the mechanics of ASMCs and the ADAM33 protein is predominantly expressed in ASMCs (6, 10, 11) . Thus, it is feasible that in asthma, the protein level of ADAM33 is altered, which may correlate with the mechanics of ASMCs and contribute to the induction of asthma development.
To test this hypothesis, Sprague Dawley (SD) rats were sensitized with OVA for up to 12 weeks to model chronic asthma. The protein expression of ADAM33 was then measured, along with the stiffness and contractility, traction force generation and cytoskeletal structure of the ASMCs obtained from the animal models at different time points of sensitization. The results demonstrated that the protein expres-ADAM33 protein expression and the mechanics of airway smooth muscle cells are highly correlated in ovalbumin-sensitized rats sion of ADAM33 in the ASMCs of the sensitized rats increased compared with that of the controls. However, the increase peaked at 4 weeks of sensitization, and gradually declined as sensitization continued. Notably, the majority of mechanical properties appeared to change similarly throughout the sensitization period, resulting in a positive correlation between the protein expression of ADAM33 and the stiffness, traction force generation, and expression of viculin and F-actin. This implied that ADAM33 protein expression was correlated with the mechanics of ASMCs, and that the two may be concurrently involved in the pathogenesis and progression of asthma.
Materials and methods
Animal models and ASMC culture. Male SD rats (purchased from Chonqing Medical School, Chonqing, China) were sensitized by OVA to simulate asthma symptoms, following a standard protocol as described previously (12, 13) . The study was approved by the Animal Investigational Committee of Chongqing Medical School, Chongqing, China. In brief, the rats were injected with 1% OVA and 10% Al(OH) 3 in NaCl solution on days 1 and 7. From day 14, the rats were sensitized by OVA three times per week for 4, 6 or 12 weeks, to mimic chronic asthma at different stages (data not shown). Rats recieving the same treatment schedule, but with saline instead of OVA, were used as controls. At given time points of sensitization (at 4, 6 and 12 weeks), primary ASMCs were isolated from the SD rats and cultured in vitro according to the method described previously (14) . In this study, all the cells used were between passages 2 to 5.
Immunoblotting for ADAM33 protein. Protein expression of ADAM33 was assessed by western blot analysis as described previously (1, 9) . Briefly, when the ASMCs grew to 90% confluence, they were lysed with 1X loading buffer (Beyotime Biotech, Jiangsu, China) to extract the total proteins. Subsequently, the proteins from each group, together with β-tubulin as the reference marker, were loaded in an equal volume of solution onto 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels. Western blot analysis was performed using a specific primary antibody for ADAM33 protein [AV49937; Sigma-Aldrich, St. Louis, MO, USA; diluted to 1:200 in 1% bovine serum albumin (BSA)] and β-tubulin (Cell Signaling Technology, Inc., Beverly, MA, USA) overnight at 4˚C. Subsequently, detection was performed using the corresponding horseradish peroxidase-conjugated secondary antibodies (Wuhan Boster, Biological Technology, Ltd., Wuhan, China). The protein expression of ADAM33 and β-tubulin was detected using an enhanced chemiluminescence kit (Beyotime Biotech, Jiangsu, China), and the ratio of the protein expression of ADAM33 to that of β-tubulin was used for quantitative assessment.
Assessment of ASMC stiffness and contractility. To assess ASMC mechanical properties, the cell stiffness and contractility were measured by optical magnetic twisting cytometry (OMTC), as previously described (13, 15 . The beads were then magnetized horizontally and twisted in an oscillatory magnetic field at a frequency of 0.1-100 Hz. The cell stiffness (G') was measured as the ratio between the applied magnetic torque and bead displacement (Pa/nm). The change in cell stiffness in response to stimulation by contractile agonist, such as KCl, was observed in the ASMCs. ASMC stiffness was measured at a constant oscillation frequency (0.3 Hz) for up to 60 sec. Following this, the contractile agonist, KCl (80 mM; iso-osmotic in this case), was immediately added to the cells. In response to KCl, the cells contracted, and thus, the cell stiffness increased in ~1 min. The ratio between the cell stiffness following the addition of KCl and prior to the addition of KCl was defined as the contractility of the ASMCs (16) .
Assessment of traction force generation by ASMCs.
Traction force generated by ASMCs was measured using an elastic polyacrylamide gel substrate embedded with 0.2 -µm diameter fluorescence beads (F8811; Invitrogen Life Technologies, Carlsbad, CA, USA) as described previously (17, 18) . Briefly, the polyacrylamide gel was prepared by adjusting the ratio of 40% acrylamide and 2% bis-acrylamide to produce a gel with a Young's modulus of 4 kPa. The prepared gel was placed in a cell culture dish with a glass bottom (to enable microscopy) and allowed to polymerize, forming an elastic substrate with a diameter of ~18 mm and a thickness of 0.1 mm. Following gel polymerization, the substrate was activated by sulfo-SANPAH (Pierce Biotechnology, Inc., Rockford, IL, USA) and coated with 0.2 mg/ml collagen solution (type I) overnight at 4˚C. The following day, the substrate was hydrated with 2 ml Dulbecco's modified Eagle's medium/F-12 and incubated at 37˚C and 5% CO 2 for ≥24 h prior to use.
Cells were seeded onto the polyacrylamide gel substrate at a density of ~2000-5000 cells/well, incubated for 12 h to allow the cells to attach to the substrate and cultured for ≥12 h in serum-free medium. Single ASMCs were imaged with phase contrast by an inverted optical microscope (Leica DMI6000B; Leica Microsystems CMS GmbH, Wetzlar, Germany) and then detached from the substrate by trypsinization. Fluorescence imaging of the fluorescent beads embedded in the gel substrate was conducted with the inverted optical microscope prior to and following cell detachment. The traction force generated by the cells was subsequently computed by the displacement field of the elastic substrate as measured by the positions of the embedded fluorescent beads prior to and following cell detachment (18) .
Assessment of the ASMC cytoskeletal structure. To assess the cytoskeletal structure, ASMCs were labeled with fluorescent probes for vinculin and F-actin, and analyzed by confocal microscopy. Vinculin and F-actin are essential components of the focal adhesions and the microfilament cytoskeleton, respectively, and are therefore commonly used to visualize and evaluate the structure of the cytoskeleton (17, 19) . The ASMCs were fixed with 4% formaldehyde for ~20 min, washed with phosphate-buffered saline (PBS) and permeabilized with 0.2% Triton X-100 in PBS for 5 min at room temperature. Following washing with PBS, cells were treated with a blocking solution (1% BSA) for 30 min at room temperature.
To label vinculin with a fluorescent probe, the cells were incubated with monoclonal anti-vinculin antibody (Abcam, Cambridge, UK; 1:200 dilution in 1% BSA) overnight at 4˚C. The cells were washed with PBS, and further incubated with the secondary antibody, rhodamine labeled goat anti-mouse IgG (ProteinTech, Chicago, IL, USA; 1:100 dilution in 1% BSA) for 2 h at room temperature. To label F-actin with a fluorescent probe, the cells were incubated with fluorescein isothiocyanate-phalloidin (5 µg/ml; cytoskeleton) for 30 min at room temperature. The fluorescently labeled cells were subsequently observed and imaged by confocal microscopy (Leica TCS SP5 II, Leica Microsystems CMS GmbH). The fluorescence intensity of the labeled vinculin and F-actin in each cell was quantified by analysis of the fluorescent confocal microscopy images, using Image-Pro Plus software (Media Cybernetics, Inc., Rockville, MD, USA).
Correlation analysis and statistics.
Pearson's correlation was tested using the Statistical Product and Service Solution v.17 (SPSS, Inc., Chicago, IL, USA). Significant differences were analyzed using one-way analysis of variance followed by Tukey's test for multiple comparisons between groups, using SigmaPlot 12.0 (SysStat Software, San Jose, CA, USA). P<0.05 was considered to indicate a statistically significant difference. Fig. 1 demonstrates the levels of the protein expression of ADAM33 in ASMCs from rats recieving OVA sensitization for 4, 6 or 12 weeks, and from the controls, as quantified by western blot analysis. Fig. 1A shows the western blot image in which an intense band of ~55 kDa, corresponding to the molecular weight of ADAM33 protein was observed, indicating ADAM33 expression. Lanes 1-4 in Fig. 1A represent samples from the controls and the rats sensitized by OVA for 4, 6 and 12 weeks, respectively. Fig. 1B shows the quantitative results of the western blot analysis, as defined by the ratio of the expression of ADAM33 protein to that of β-tubulin. Compared with the controls, the protein expression of ADAM33 was increased in all ASMCs from the OVA-sensitized rats, and this increase peaked when the rats were sensitized for 4 weeks and then gradually declined as OVA sensitization continued (P<0.001).
Results

OVA sensitization induces ADAM33 protein expression.
OVA sensitization leads to stiffening, but no change in contractility, of the ASMCs. Fig. 2 demonstrates the cell stiffness and contractility of ASMCs from rats with or without OVA sensitization, as measured by OMTC. Fig. 2A shows the log-log plot of the cell stiffness (G') versus the frequency of measurement (0.1-100 Hz). In all cases, the cell stiffness exhibited typical power-law behavior, in which cell stiffness increased with frequency (ƒ) as a power-law response (G'~ƒ α ), where α is the power-law exponent that is typically between 0.1 and 0.3 for living cells (20) . The magnitude of the cell stiffness was observed to be in the ascending order of 12 weeks, control, 6 weeks and 4 weeks, and α also increased with the same trend. This trend was further demonstrated by the cell stiffness measured at a single constant frequency (0.3 Hz), the G 0 of ASMCs from rats with or without OVA sensitization. Compared with the control rats, G 0 in the OVA-sensitized rats significantly increased, peaked when the rats were sensitized for 4 weeks (P<0.05) and gradually declined with continued sensitization (Fig. 2B) . Fig. 2C shows a typical time course plot of cell stiffness in response to KCl stimulation. Prior to the addition of KCl, the cell stiffness fluctuated with an averaged baseline level (G 0 ). Following the addition of KCl to the ASMCs, the cells responded by contraction that rapidly increased the cell stiffness to a higher level (G KCl ) in ~1 min. Thus, the contractility of ASMCs with KCl stimulation was quantified as the ratio between the cell stiffness following KCl activation (G KCl ) and the baseline cell stiffness (G 0 ), i.e. G KCl /G 0 . As demonstrated in Fig. 2D , OVA sensitization did not result in a significant change in the contractility of ASMCs from SD rats.
OVA-sensitization results in an acute increase in the traction force of ASMCs. Fig. 3 demonstrates the effect of OVA sensitization on the traction force generated by ASMCs. Fig. 3A shows the phase-contrast image of a single ASMC cultured on the polyacrylamide substrate, and Fig. 3B demonstrates the field of the traction force generated in this cell. From the traction force field, the net contractile moment of each ASMC was quantified. In Fig. 3C , it was observed that compared with the controls, the traction force generated by ASMCs was significantly greater in the rats that had been sensitized by OVA for 4 weeks (P<0.05), and marginally (but not significantly) enhanced for the longer duration of OVA sensitization. mechanical properties, including the cell stiffness, traction force, and levels of vinculin and F-actin (Table I) .
Discussion
The present study demonstrated that OVA sensitization of SD rats resulted in increased protein expression levels of ADAM33 in the ASMCs, in a time-dependent manner. The protein expression levels of ADAM33 in the ASMCs reached a maximum at ~4 weeks of OVA sensitization, and then gradually subsided as OVA sensitization continued. Notably, the mechanical properties of the ASMCs, including cell stiffness and traction force, were altered during the course of OVA sensitization in the same manner as that of the ADAM33 protein.
The OVA-induced alteration of the ASMC mechanics and ADAM33 protein expression were positively correlated. These results implied that ADAM33 protein expression was correlated with the mechanics of the ASMCs during the pathogenesis and progression of asthma. The protein expression of ADAM33 was increased in the ASMCs of the OVA-sensitized rats, which was consistent with a previous study that demonstrated that the expression of ADAM33 was increased in asthmatic patients (1) . However, in this study, ASMCs were studied in vitro, and the protein expression of ADAM33 was likely to be variable as the primary cells were passaged over time (21) . To control for this passagedependent variability, only the cells between passages 2 to 5 were used in the present study, and the relative expression of the ADAM33 protein was obtained from cells of the same passage.
ASMC mechanics are generally recognized as the final pathway to AHR that characterizes asthma (11, 13) . In the present study, it was demonstrated that in the OVA-sensitized SD rat models of asthma, the magnitude of ASMC stiffness increased during OVA sensitization. Notably, the time dependence of the cell stiffness of the ASMCs appeared to be similar to that of the protein expression of ADAM33. Statistical analysis verified that the stiffness was positively correlated with the ADAM33 protein expression in the ASMCs of the OVA-sensitized rats (Pearson's correlation coefficient, 0.864). ASMC stiffness also exhibited characteristic power-law behavior when measured over a range of frequencies, which was consistent with previous studies (15, 22) . However, it was noted that the contractility of the ASMCs as determined by the stiffness increase in response to KCl stimulation was not affected by OVA sensitization. The absence of an effect of OVA-sensitization on the KCl-induced contractility in the ASMCs was somewhat but not completely surprising, due to the nature of KCl stimulation. As a non-specific contractile agonist, it is possible that the OVA sensitization was only effective on certain structure(s) of the contractile machinery of the ASMCs, which KCl was unable to target or activate. Specific agonists, such as histamine, that target the G-protein coupled receptors may be used to further investigate this.
Fourier transform traction microscopy was utilized to assess the ASMCs for the ability to generate traction force at the single-cell level. The results demonstrated that compared with the non-sensitized rats, ASMCs from the OVA-sensitized rats generated greater traction force, and the extent of traction force enhancement was also positively correlated with the increase in ADAM33 protein expression during OVA sensitization (Pearson's correlation coefficient, 0.716). The enhancement of traction force generation by the ASMCs may be attributed to various factors, including a strengthened cytoskeletal structure, the interaction of actin and myosin filaments (19) and enhanced focal adhesions due to an increased quantity of structural and signaling proteins, such as vinculin (23) . These factors, separately or combined, may enhance the physical links between the cytoskeleton and the extracellular matrix, exerting a greater traction force to the extracellular matrix (24) . In the present study, the results of the confocal microscopy of the ASMCs that were fluorescently labeled for vinculin and F-actin demonstrated that the ASMCs from the OVA-sensitized rats exhibited a greater level of fluorescence intensity of vinculin and F-actin compared with those from the non-sensitized rats. The increases in vinculin and F-actin were also positively correlated with the increased protein expression of ADAM33 during OVA-sensitization (Pearson's correlation coefficients, 0.774 and 0.662 for vinculin and F-actin, respectively). This suggests a possible signaling pathway of ASMCs in which ADAM33 protein modulates cell mechanics via the regulation of cytoskeletal proteins, such as vinculin and F-actin.
Furthermore, the results demonstrated that the effects of OVA sensitization on the ASMCs were greatest when the rats were sensitized for 4 weeks, and then they gradually decreased regardless of the continuation of OVA sensitization. This time dependence of the efficacy of OVA sensitization may be largely attributed to the phenomenon of desensitization, which has been observed in repeatedly challenged rats and guinea pigs (25, 26) . The rate of desensitization was faster for ASMC mechanics compared with that of the expression of the ADAM33 protein. This difference implied that the ASMC mechanics that characterize airway function may be more sensitive and adaptable to the presence of an allergen compared with biological targets, such as ADAM33 protein (27) ; however, further studies are required.
To the best of our knowledge, this study demonstrated for the first time in vivo that OVA sensitization of SD rats led to the increased expression of ADAM33 protein in ASMCs. OVA sensitization also resulted in increased stiffness, traction force and expression of vinculin and F-actin in ASMCs. The extent of these changes were time-dependent during OVA sensitization. Notably, the change in the expression of ADAM33 protein in the ASMCs was correlated with the changes in ASMC mechanics, including cell stiffness, traction force and the expression of vinculin and F-actin. This suggested that the ADAM33 protein and the ASMC mechanics may be concordantly involved in the pathogenesis and progression of asthma. As ADAM33 is an asthma susceptibility gene and ASMC mechanics are the common pathway to AHR that is the hallmark of asthma, these results may have identified a potential mechanism through which ADAM33 contributes to the pathogenesis of asthma, and thus may aid in the development of novel ADAM33-based therapeutics to treat asthma. 
